CG Oncology (CGON) Net Equity Issued and Repurchased (2024 - 2026)

CG Oncology's Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $391.5 million for Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $391.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $761.8 million (changed N/A YoY) and the FY2025 annual result came in at $147.4 million, down 33.91% from the prior year.
• Net Equity Issued and Repurchased was $391.5 million for Q1 2026 at CG Oncology, up from $98.4 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $391.5 million in Q1 2026 and bottomed at $48.7 million in Q3 2025.
• A 3-year average of $190.4 million and a median of $160.8 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• Peak annual rise in Net Equity Issued and Repurchased reached 55.87% in 2025, while the deepest fall reached 55.87% in 2025.
• CG Oncology's Net Equity Issued and Repurchased stood at $223.1 million in 2024, then plunged by 55.87% to $98.4 million in 2025, then jumped by 297.72% to $391.5 million in 2026.
• Business Quant data shows CGON's Net Equity Issued and Repurchased at $391.5 million in Q1 2026, $98.4 million in Q4 2025, and $48.7 million in Q3 2025.